

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

CSPC PHARMACEUTICAL GROUP LIMITED,
CSPC OUYI PHARMACEUTICAL CO., LTD.,
AND CONJUPRO BIOTHERAPEUTICS, INC.,
Petitioners,

v.

IPSEN BIOPHARM LTD.,
Patent Owner.

Case No. IPR2025-00505
U.S. Patent No. 11,344,552

Patent Owner's Current Exhibit List

EXHIBIT LIST

No.	Exhibit Description	Previously Submitted
2001	File History of U.S. Patent No. 11,344,552, March 6, 2018 Notice of References Cited (“March 6, 2018 Notice”)	X
2002	File History of U.S. Patent No. 11,344,552, July 8, 2019 Information Disclosure Statement by Applicant (“July 8, 2019 IDS”)	X
2003	File History of U.S. Patent No. 11,344,552, August 26, 2021 Information Disclosure Statement by Applicant (“August 26, 2021 IDS”)	X
2004	Robert De W. Marsh et al., <i>Pancreatic cancer and FOLFIRINOX: a new era and new questions</i> , Cancer Med. 2015 Jun;4(6):853-63 (2015) (“Marsh”)	X
2005	Somala Mohammed et al., <i>Pancreatic cancer: Advances in treatment</i> , 20(28) World J. Gastroenterol 9354 (2014) (“Mohammed”)	X
2006	Maria L. Rossi et al., <i>Therapeutic options for the management of pancreatic cancer</i> , 20(32) World J. Gastroenterol. 11142 (2014) (“Rossi”)	X
2007	Matias E. Valsecchi et al., <i>Recent Treatment Advances and Novel Therapies in Pancreas Cancer: A Review</i> , 45 J. Gastrointest. Cancer 190 (2014) (“Valsecchi”)	X
2008	Biotechnology Innovation Organization et al., <i>Clinical Development Success Rates 2006-2015</i> (2016) (“BIO study”)	X
2009	Ramya Thota et al., <i>Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?</i> , 46(2) Pancreas 143 (2017) (“Thota”)	X
2010	Mark J. Ratain, <i>Phase II Oncology Trials: Let's Be Positive</i> , 11(16) Clin. Cancer Rsch. 5561 (2005) (“Ratain 2005”)	X
2011	Eastern Research Group, Inc., <i>Examination of Clinical Trial Costs and Barriers for Drug Development</i> (2014) (“ERG 2014”)	X
2012	Ramaswamy Govindan, <i>Phase III failure rates in oncology drugs unacceptable</i> , 16(8) Oncology News Int'l (2007) (“Govindan”)	X

2013	Anneke T. Schroen et al., <i>Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials</i> , 7 Clin. Trials 312 (2010) (“Schroen”)	X
2014	Maria Syl D. De La Cruz, et al., <i>Diagnosis and Management of Pancreatic Cancer</i> , Am Fam Physician, 89(8):626-632 (2014) (“De La Cruz”)	X
2015	Marvin Schober, et al., <i>New Advances in the Treatment of Metastatic Pancreatic Cancer</i> , Digestion, 92(3):175-184 (2015) (“Schober”)	X
2016	Maria L. Rossi et al., <i>Therapeutic options for the management of pancreatic cancer</i> , 20(32) World J. Gastroenterol. 11142 (2014) (“Rossi”)	X
2017	File History of U.S. Patent No. 11,344,552, Feb. 25, 2022 Remarks (“February 25, 2022 Remarks”)	X
2018	Dorland's Illustrated Medical Dictionary (32nd ed. 2012) (“Dorland's Dictionary”)	X
2019	Stedman's Medical Dictionary for the Health Professions and Nursing (7th ed. 2012) (“Stedman's Dictionary”)	X
2020	Taber's Cyclopedic Medical Dictionary (22nd ed. 2013) (“Taber's Dictionary”)	X
2021	Conjupro Biotherapeutics, Inc. et al, Answer to Complaint for Patent Infringement, Affirmative Defenses and Counterclaims, No. 1:24-cv-04991-RMB-MJS (July 8, 2024 D.N.J.) (“CSPC's Answer”)	X
2022	CSPC Pharmaceutical Group Limited, Voluntary Announcement, <i>Exclusive License Agreement with Cipla USA, Inc. for Irinotecan Liposome Injection</i> , May 15, 2025 (“CSPC Press Release”)	X
2023	Original French language publication of Supplemental Protocol to: Thierry Conroy et al., <i>FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer</i> , N. Engl. J. Med., 364(19):1817-25 (2011), available at https://www.nejm.org/doi/full/10.1056/NEJMoa1011923 (“Original Conroy Protocol”)	X
2024	Matias E. Valsecchi et al., <i>Recent Treatment Advances and Novel Therapies in Pancreas Cancer: A Review</i> , 45 J. Gastrointest. Cancer 190 (2014) (“Valsecchi”)	X

2025	Robert De W. Marsh et al., <i>Pancreatic cancer and FOLFIRINOX: a new era and new questions</i> , Cancer Med. 2015 Jun;4(6):853-63 (2015) (“Marsh”)	X
2026	Samir D. Undevia, et al., <i>Pharmacokinetic Variability of Anticancer Agents</i> , Nat Rev Cancer, 5(6):447-458 (2005) (“Undevia”)	X
2027	U.S. Patent No. 7,807,350 to Ratain et al. (“the ’350 patent”)	X
2028	Mark J. Ratain, et al., <i>Dose-finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients with Cancer</i> , J Clin Oncol., 32(22):2328-2334 (2014) (“Ratain 2014”)	X
2029	Dylan M. Bach, et al., <i>Therapeutic drug monitoring in cancer chemotherapy</i> , Bioanalysis. 2010 May;2(5):863-79 (“Bach”)	X
2030	H Gurney, et al., <i>How to calculate the dose of chemotherapy</i> , Br J Cancer 86, 1297–1302 (2002) (“Gurney”)	X
2031	Alnaim, <i>Therapeutic Drug Monitoring of Cancer Chemotherapy</i> , J Oncol Pharm Pract., 13(4):207-221 (2007) (“Alnaim”)	X
2032	Biotechnology Innovation Organization et al., <i>Clinical Development Success Rates 2006-2015</i> (2016) (“BIO study”)	X
2033	Ramya Thota et al., <i>Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?</i> , 46(2) Pancreas 143 (2017) (“Thota”)	X
2034	Xiayu Jiao, et al., <i>Comparative effectiveness of NALIFIROX vs. FOLFORINOX in pancreatic cancer</i> , JCO 42, 4160-4160(2024) (“Jiao”)	X
2035	Zuojuan Xiang et al., <i>Cost-effectiveness analysis of first-line combination chemotherapy regimens for metastatic pancreatic cancer and evidence-based pricing strategy of liposomal irinotecan in China</i> . Front Pharmacol. 2024 Dec 20;15:1488645 (“Xiang”)	X
2036	NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma Version 2.2015 (“March 2015 NCCN Guidelines”)	
2037	M.J. Ratain et al., <i>Optimising the design of phase II oncology trials: the importance of randomisation</i> , Eur. J. Cancer, 2009 Jan;45(2):275-80 (2009) (“Ratain 2009”)	

2038	M. Ychou, et al., <i>An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumors</i> , Ann. Oncol., 14(3):481-89 (2003) (“Ychou”)	
2039	S. Gourgou-Bourgade et al. <i>Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial</i> , J. Clin. Oncol., 31, 23-29 (2013) (“Gourgou-bourgade”)	
2040	FDA Supplemental Approval Letter for the new indication of Onivyde® in combination with oxaliplatin, fluorouracil and leucovorin, for the first-line treatment of adult patients with metastatic pancreatic adenocarcinoma, dated February 13, 2024 (“FDA Approval Letter”)	
2041	S.Y. Oh et al., <i>Pilot study of irinotecan/oxaliplatin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil-refractory pancreatic cancer</i> , Invest. New Drugs, 2010 Jun;28(3):343-49 (2010) (“Oh”)	
2042	H. Zhang et al., <i>Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomized-controlled open-label Phase II study</i> , Gastroenterol. Rep., 2023 Feb 3;11:goac088 (2023) (“Zhang”)	
2043	K.S. Gunturu, et al., <i>FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity</i> , Med. Oncol. 2013 Mar;30(1):361 (2013) (“Gunturu”)	
2044	L. Amiri-Kordestani, et al., <i>Why do phase III clinical trials in oncology fail so often?</i> , J. Natl. Cancer Inst., 2012 Apr 18;104(8):568-9 (2012) (“Amiri-Kordestani”)	
2045	B. Booth, et al., <i>Oncology's trials</i> , Nat. Rev. Drug Disc. 2(8):609-10 (2003) (“Booth”)	
2046	E. Vasile, et al., <i>Neoadjuvant Modified Folfoxiri in Locally advanced Pancreatic Cancer</i> , Ann. Oncol., 23:ix241 (2012) (“Vasile”)	
2047	E.S. James et al., <i>Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally</i>	

	<i>advanced (LAPC) and metastatic pancreatic cancer (MPC)</i> , J. Clin. Oncol. 32, 256-256 (2014) (“James”)	
2048	S.M. Stein et al., <i>Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer</i> , Br. J. Cancer, 2016 Mar 29;114(7):737-43 (2016) (“Stein”)	
2049	K. Yoshida et al., <i>A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer</i> , Oncotarget. 2017 Nov 30;8(67):111346-111355 (2017) (“Yoshida”)	
2050	X. Li et al., <i>Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population</i> , Cancer Lett. 2017 Oct 10;406:22-26 (2017) (“Li”)	
2051	M. Ozaka et al., <i>A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer</i> , Cancer Chemother. Pharmacol. 2018 Jun;81(6):1017-1023 (2018) (“Ozaka”)	
2052	Z.Q. Wang et al., <i>The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer</i> , Cancer Commun. (Lond). 2019 May 8;39(1):26 (2019) (“Wang”)	
2053	R.K. Ramanathan et al., <i>Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313</i> , J. Clin. Oncol. 2019 May 1;37(13):1062-1069 (2019) (“Ramanathan”)	
2054	T. Wei et al., <i>Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer</i> , Mol. Cancer Ther., 2019 Jan;18(1):196-203 (2019) (“Wei”)	
2055	C. Vivaldi et al., <i>Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study</i> , Cancers (Basel). 2019 Jul 4;11(7):939 (2019) (“Vivaldi 2019”)	
2056	P.F. Peddi et al., <i>A. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma</i> , JOP. 2012 Sep 10;13(5):497-501 (2012) (“Peddi”)	

2057	M.A. Lowery et al., <i>Activity of front-line FOLFIRINOX (FFX) in stage III/IV pancreatic adenocarcinoma (PC) at Memorial Sloan-Kettering Cancer Center (MSKCC)</i> , J. Clin. Oncol. 30, 4057-4057 (2012) (“Lowrey”)	
2058	P.J. Hosein et al., <i>A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma</i> , BMC Cancer. 2012 May 29;12:199 (2012) (“Hosein”)	
2059	E. Ghorani et al., <i>Safety and efficacy of modified FOLFIRINOX for advanced pancreatic adenocarcinoma: a UK single-center experience</i> , Oncology 2015; 89(5):281-7 (2015) (“Ghorani”)	
2060	Y. Kaga et al., <i>Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX</i> , Oncotarget, 2016; 7: 67314-67320 (2016) (“Kaga”)	
2061	V.H.F. de Jesus et al., <i>Retrospective comparison of the efficacy and the toxicity of standard and modified FOLFIRINOX regimens in patients with metastatic pancreatic adenocarcinoma</i> , J. Gastrointest. Oncol. 2018 Aug;9(4):694-707 (2018) (“de Jesus”)	
2062	H. Kang et al., <i>Comparison of Efficacy and Safety between Standard-dose and Modified-dose FOLFIRINOX as a First-line Treatment of Pancreatic Cancer</i> , World J. Gastrointest. Oncol. 2018 Nov 15; 10(11):421-430 (2018) (“Kang”)	
2063	Y. Yamada et al., <i>Severe Neutropenia is Associated with Better Clinical Outcomes in Patients with Advanced Pancreatic Cancer Who Receive Modified FOLFIRINOX Therapy</i> , Cancers (Basel), 2018 Nov 16;10(11):454 (2018) (“Yamada”)	
2064	E. Eraslan, et al., <i>First Line Modified Folfirinox versus Gemcitabine for Advanced Pancreatic Cancer: A Single Institution Retrospective Experience</i> , J. Oncol. Sci., Apr. 2019 5:1 (2019) (“Eraslan”)	
2065	T. Sasaki et al., <i>Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis, In Vivo</i> . 2019 Jan-Feb;33(1):271-276 (2019) (“Sasaki”)	
2066	C. Vivaldi et al., <i>Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in</i>	

	<i>pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel</i> , Pharmacogenomics J. 2021 Apr;21(2):233-242 (2021) (“Vivaldi 2021”)	
2067	L. Cavanna et al., <i>Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience</i> , Onco. Targets Ther. 2019 Apr 23;12:3077-3085 (2019) (“Cavanna”)	
2068	H. Cui et al., <i>A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer</i> , Med. Sci. Monit. 2020 Oct 26;26:e927654 (2020) (“Cui”)	
2069	V. Pacheco-Barcia et al., <i>A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer</i> , Pancreatology 2020 Mar;20(2):254-264 (2020) (“Pacheco-Barcia”)	
2070	T. Takeda et al., <i>Improved prognosis of pancreatic cancer patients with peritoneal metastasis</i> , Pancreatology 2021 Aug;21(5):903-911 (2021) (“Takeda”)	
2071	Y. Zhou et al., <i>Delta HU is a potential marker to predict chemotherapy response for unresectable pancreatic ductal adenocarcinoma</i> , Pancreatology 2021 Jun;21(4):763-770 (2021) (“Zhou”)	
2072	P.E. Oberstein et al., <i>Pancreatic cancer: why is it so hard to treat?</i> , Therap. Adv. Gastroenterol. 2013 Jul;6(4):321-37 (2013) (“Oberstein”)	
2073	Deposition Transcript of Mark J. Ratain In the Matter of CSPC Pharma vs. Ipsen Biopharm, dated October 24, 2025 (“Ratain Deposition”)	
2074	Label for CAMPTOSAR® (Irinotecan) Injection, intravenous infusion, Revised 12/2014 (“Camptosar 2014 Label”)	
2075	J.J. Knox et al. <i>Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01</i> , J. Clin. Oncol. 42, LBA4004-LBA4004 (2024) (“Knox II”)	
2076	Declaration of Paul E. Oberstein	
2077	Declaration of June A. Munford	

CERTIFICATE OF SERVICE (37 C.F.R. § 42.6(E))

The undersigned hereby certifies that on November 10, 2025 copies of the foregoing document and supporting exhibits were served upon the following parties via electronic mail, with a copy to ipdocket@foxrothschild.com (referencing Attorney Docket No. 340008.00021):

Lead Counsel:

Luke Toft (Reg. No. 75,311)
ltoft@foxrothschild.com
Fox Rothschild LLP
33 South 6th Street, Suite 3600
Minneapolis, MN 55402
Tel: (612) 607-7336
Fax: (612) 607-7100

Backup Counsel:

Joe Chen (Reg. No. 70,066)
joechen@foxrothschild.com
Fox Rothschild LLP
212 Carnegie Center, Suite 400
Princeton, NJ 08540
Tel: (609) 844-3024
Fax: (609) 896-1469

Howard S. Suh (pro hac vice to be filed)
hsuh@foxrothschild.com
Fox Rothschild LLP
101 Park Avenue, 17th Floor
New York, NY 10178
Tel: (212) 878-7914
Fax: (212) 692-0940

Date: November 10, 2025

By: /s/ James Glass

James M. Glass (Reg. No. 46,729)
QUINN EMANUEL URQUHART &
SULLIVAN LLP
295 5th Ave.
New York, New York 10016
Email: jimglass@quinnemanuel.com
Phone: 212-849-7142
Fax: 212-849-7100

Counsel for Patent Owner